Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial

The Lancet Gastroenterology and Hepatology

Volumn 5, Issue 7, 2020, Pages 658-666

  Andresen, Viola ^a   Gschossmann, Jürgen ^b   Layer, Peter ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b Clinic Forchheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIFIDOBACTERIUM BIFIDUM MIMBB75; INACTIVATED VACCINE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BIFIDOBACTERIUM BIFIDUM; CANCER PATIENT; CELL VIABILITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFECTION SENSITIVITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MULTICENTER STUDY; NUMERIC RATING SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECT; EPIDEMIOLOGY; GERMANY; INTESTINE; MALE; MICROBIOLOGY; MIDDLE AGED; PAIN MEASUREMENT; PHYSIOLOGY; SAFETY; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; BIFIDOBACTERIUM BIFIDUM; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; PROBIOTICS; SAFETY; TREATMENT OUTCOME;

EID: 85086338666     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(20)30056-X     Document Type: Article

References (34)

1. Lovell, RM, Ford, AC, Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol 107 (2012), 1793–1801.
2. Müller-Lissner, SA, Bollani, S, Brummer, RJ, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 64 (2001), 200–204.
3. European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf. (Accessed 2 March 2020)
4. Rome Foundation. Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis 15 (2006), 307–312.
5. Chang, L, Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 20:suppl 7 (2004), 31–39.
6. Piche, T, Barbara, G, Aubert, P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58 (2009), 196–201.
7. Vivinus-Nébot, M, Dainese, R, Anty, R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 107 (2012), 75–81.
8. Marshall, JK, Thabane, M, Garg, AX, Clark, W, Meddings, J, Collins, SM, Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 20 (2004), 1317–1322.
9. Guglielmetti, S, Mora, D, Gschwender, M, Popp, K, Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33 (2011), 1123–1132.
10. Lopetuso, LR, Scaldaferri, F, Bruno, G, Petito, V, Franceschi, F, Gasbarrini, A, The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci 19 (2015), 1068–1076.
11. Resta-Lenert, S, Barrett, KE, Probiotics and commensals reverse TNF-α- and IFN-γ-induced dysfunction in human intestinal epithelial cells. Gastroenterology 130 (2006), 731–746.
12. Eun, CS, Kim, YS, Han, DS, Choi, JH, Lee, AR, Park, YK, Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS 119 (2011), 49–56.
13. Guglielmetti, S, Tamagnini, I, Mora, D, et al. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells. Appl Environ Microbiol 74 (2008), 4695–4702.
14. Pan, WH, Li, PL, Liu, Z, The correlation between surface hydrophobicity and adherence of Bifidobacterium strains from centenarians' faeces. Anaerobe 12 (2006), 148–152.
15. Brenner, DM, Chey, WD, Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord 9 (2009), 7–15.
16. Ducrotté, P, Sawant, P, Jayanthi, V, Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 18 (2012), 4012–4018.
17. Farup, PG, Jacobsen, M, Ligaarden, SC, Rudi, K, Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract, 2012, 2012, 214102.
18. Layer, P, Andresen, V, Pehl, C, et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM)1. Z Gastroenterol 49 (2011), 237–293.
19. Majeed, M, Nagabhushanam, K, Natarajan, S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J, 15, 2016, 21.
20. Ludidi, S, Jonkers, DM, Koning, CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 26 (2014), 705–714.
21. Hod, K, Sperber, AD, Ron, Y, et al. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil, 29, 2017, e13037.
22. Adams, CA, The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 23 (2010), 37–46.
23. Isolauri, E, Juntunen, M, Rautanen, T, Sillanaukee, P, Koivula, T, A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 88 (1991), 90–97.
24. Mitra, AK, Rabbani, GH, A double-blind, controlled trial of bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli. Gastroenterology 99 (1990), 1149–1152.
25. Tsuchiya, J, Barreto, R, Okura, R, Kawakita, S, Fesce, E, Marotta, F, Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5 (2004), 169–174.
26. Lahtinen, SJ, Probiotic viability—does it matter?. Microb Ecol Health Dis, 23, 2012, 18567.
27. Hall, KT, Lembo, AJ, Kirsch, I, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One, 7, 2012, e48135.
28. Patel, SM, Stason, WB, Legedza, A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 17 (2005), 332–340.
29. Ford, AC, Harris, LA, Lacy, BE, Quigley, EMM, Moayyedi, P, Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 48 (2018), 1044–1060.
30. Liang, D, Longgui, N, Guoqiang, X, Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis. Medicine, 98, 2019, e16068.
31. Meier, R, Lied, GA, Rasmussen, SH, Asiller, ÖÖ, Probiotics in irritable bowel syndrome. Ann Nutr Metab 57:suppl (2010), 12–13.
32. Ouwehand, AC, Salminen, SJ, The health effects of cultured milk products with viable and non-viable bacteria. Int Dairy J 8 (1998), 749–758.
33. Besselink, MGH, van Santvoort, HC, Buskens, E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008), 651–659.
34. Enache-Angoulvant, A, Hennequin, C, Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41 (2005), 1559–1568.